Author:
,Vetapalem Rajani,Prasad Rajendra Y., ,Rao Lakshmana A.,
Abstract
Combining dapagliflozin and saxagliptin presents a promising strategy for managing type 2 diabetes mellitus by leveraging their distinct, yet complementary, mechanisms of action. A novel bilayer tablet with a 5 mg sustained release layer of saxagliptin and a 10 mg immediate release layer of dapagliflozin was developed. Live animal studies (in vivo) were conducted on rabbits to evaluate the effects of an optimized formulation. Based on in vivo performance, the novel bilayer tablets demonstrated greater bioavailability. A new, easy-to-use technique was created to simultaneously measure the two drugs (dapagliflozin and saxagliptin) in rabbit blood plasma. Evaluation of the technique’s parameters were done on rabbit plasma in accordance with ICH guidelines. The parameters for pharmacokinetic analysis were (AUC0-∞), (Cmax), Tmax and others. Direct calculations of the Cmax and Tmax were made using experimental plasma concentration versus time data. The AUC0-∞ was produced by adding the computed AUC0-24h using the trapezoidal rule. Using sample analysis of variance or independent sample t tests, average data variation was compared (one way analysis of variance). Statistical significance (p=0.05) was assessed using a 95% confidence interval.
Publisher
Indian Drug Manufacturers' Association (IDMA)
Reference13 articles.
1. 1. Wise D. L.: Handbook of pharmaceutical controlled release technology, Marcel Dekker, New York, 2000, 505.
2. 2. Chein Y. W.: Novel drug delivery system, Marcel Dekker, New York, 2005, 139.
3. 3. Swarbrick J and Boylan J. C.: An encyclopedia of pharmaceutical technology, Marcel Dekker, New York, 1992, 385.
4. 4. Priyamvada B., Ganarajan G. and Preeti K.: Bilayer: a review. Int. J. Pharm. Chem. Sci., 2013, 2(4), 1788-1797.
5. 5. Abdulfatai B. O., Olusegun A. O. and Lateefat B. O.: Type 2 diabetes mellitus: a review of current trends. Oman Med. J., 2012, 27, 269-273.